Showing results (1021-1030 of 1,071) with videos related to

Sort By:
Pageof 108
Scientific Reports|October 15, 2015
The 9p21.3 risk of childhood acute lymphoblastic leukaemia is explained by a rare high-impact variant in CDKN2AJayaram Vijayakrishnan, Marc Henrion, Anthony V Moorman, et al.
Clinical & Translational Immunology|February 28, 2018
Rapid loss of group 1 innate lymphoid cells during blood stage <i>Plasmodium</i> infectionSusanna S Ng, Fernando Souza-Fonseca-Guimaraes, Fabian de Labastida Rivera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2026
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII)Vanita Noronha, Vijay Patil, Nandini Menon, et al.
International Journal of Cancer|June 12, 2014
MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP projectElena Pasquali, José C García-Borrón, Maria Concetta Fargnoli, et al.
The Lancet Regional Health. Southeast Asia|December 19, 2022
An observational multi-centric COVID-19 sequelae study among health care workersAjay Kumar Shukla, Shubham Atal, Aditya Banerjee, et al.
Blood|September 3, 2013
Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotypeGabriele Migliorini, Bettina Fiege, Fay J Hosking, et al.
Indian Journal of Pharmacology|July 9, 2025
Prescribing trends of fixed-dose combination of domperidone and proton-pump inhibitor across tertiary care centers in India, is the combination rational?Ajay Kumar Shukla, Sameer Uttamrao Khasbage, Ratinder Jhaj, et al.
Pageof 108